- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03095820
Multidomain Intervention for Older Adults With Major Depressive Disorder
A 12-week Multidomain Intervention With Contingency Management for Older Adults With Major Depressive Disorder: A Community-based Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Awareness of the necessity and importance of community-based multidomain psychosocial intervention for late-life depression has increased. However, few studies have attempted to integrate several therapeutic approaches in one intervention program.
Main objective of this study is to assess the effectiveness of a 12-week multidomain intervention with contingency management for reducing depressive symptoms in older adults with major depressive disorder.
We plan to conduct a randomized controlled parallel-design study. We plan to allocate study participants to multidomain intervention or supportive therapy group, in a 1:1 ratio. Block randomization using SAS (PLAN procedure) and sample size estimation were performed. We estimated that, with at least 40 participants per group and an attrition rate of 10%, we could achieve a power of at least 0.80 (beta = 0.2, two-tailed alpha = 0.05).
Intervention was based on the financial and human resources of a community mental health service, and involved four home visits and 12 telephone calls over 12 weeks. Four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the multidomain intervention program. To maintain participant motivation, we plan to apply contingency management based on operant conditioning theory.
The primary outcome is the change in depressive symptoms, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Secondarily, we plan to investigate changes in resting-state functional connectivity in the default mode, salience, and central executive networks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gyunggi-do
-
Suwon, Gyunggi-do, Korea, Republic of, 16499
- Ajou University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a diagnosis of non-psychotic, unipolar major depressive disorder, based on the Mini-International Neuropsychiatric Interview
- a Montgomery-Asberg Depression Rating Scale (MADRS) score of 17 or higher
- the use of antidepressants at stable dosage for at least 6 weeks prior to study entry, without any recommendation for changes in medication for the 12 weeks of the intervention. Pharmacotherapy was uncontrolled and was provided by physicians.
Exclusion Criteria:
- a history of psychiatric disorder (mental retardation, schizophrenia, bipolar disorder, and dementia)
- a history of neurological disorder, such as brain tumor, intracranial hemorrhage, subarachnoid hemorrhage, epilepsy, hydrocephalus, encephalitis, metabolic encephalopathy, or other neurologic conditions that could interfere with the study
- a history of significant hearing or visual impairment
- a history of physical illnesses that could interfere with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Supportive therapy
The control group received supportive therapy for 12 weeks.
In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth.
The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
|
|
|
Experimental: Multidomain intervention
As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program. In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale(MADRS)
Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks
|
Change from baseline depressive symptoms at 4, 8, 12 weeks
|
Baseline, 4 weeks, 8 weeks, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
resting-state fMRI
Time Frame: Baseline, 12 weeks
|
brain functional connectivity
|
Baseline, 12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sang Joon Son, MD,PhD, Ajou Univeristy School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AJIRB-SBR-SUR-15-132
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
-
Stanford UniversityNational Institute of Mental Health (NIMH)Recruiting
-
TakedaRecruitingMajor Depressive DisorderJapan
-
Neurocrine BiosciencesRecruitingMajor Depressive DisorderSpain, Serbia, United States, Bulgaria, Canada, Estonia, Italy, Poland, Taiwan, Australia, South Korea
-
Luye Pharma Group Ltd.Enrolling by invitationMajor Depressive DisorderChina
-
NeuroQore Inc.Makromed Inc.Enrolling by invitationMajor Depressive DisorderUnited States
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
All India Institute of Medical Sciences, BhubaneswarNot yet recruiting
Clinical Trials on Supportive therapy
-
University of HaifaCompletedMajor Depressive DisorderIsrael
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedOvarian Carcinoma | Malignant Uterine Neoplasm | Malignant Female Reproductive System Neoplasm | Ovarian Neoplasm | Uterine Neoplasm | Female Reproductive System Neoplasm | Suspicious for MalignancyUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
FIDMAG Germanes HospitalàriesHospital Clinic of Barcelona; Hospital del Mar; Hospital Universitari de Bellvitge and other collaboratorsCompletedBipolar DisorderSpain
-
Stanford UniversityCompletedAcute Myeloid Leukemia | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Progressive Disease | Myelodysplastic Syndrome | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer and other conditionsUnited States
-
Hospices Civils de LyonUnknownBorderline Personality DisorderFrance
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)Completed
-
Centre for Addiction and Mental HealthCompleted
-
Karolinska InstitutetCompleted